While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to ...

and re-naming itself Pfizer. The deal is the biggest ever seen in the pharma sector, and also makes it a record-breaking year for the whole sector, which has now seen acquisitions worth over $600 ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Adjusted EPS guidance incorporates a 40-cent dilution related to the Seagen acquisition. Looking ahead, Pfizer projects a 10% to 18% operational adjusted diluted EPS growth for 2025 with ~flat to ...

First, it was the Seagen acquisition, which boosted this segment by about 25%. Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...